Patent 12102531 was granted and assigned to Evalve on October, 2024 by the United States Patent and Trademark Office.
Methods, devices and systems for disabling and/or removing a mitral valve edge-to-edge repair device via minimally invasive, endovascular procedures. Additional procedures on a heart may sometimes become necessary after the installation of a mitral valve edge-to-edge repair device. To prepare for such additional procedures, the edge-to-edge repair device may be removed or disabled in minimally invasive ways (e.g., through an endovascular procedure), without requiring open access to the heart.